Search results for " Anti-Inflammatory"

showing 10 items of 42 documents

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Anti-Inflammatory Activity of Citrus bergamia Derivatives: Where Do We Stand?

2016

Inflammatory diseases affect a large portion of the worldwide population, and chronic inflammation is a major risk factor for several dangerous pathologies. To limit the side effects of both synthetic and biological anti-inflammatory drugs, the use of herbal medicines, nutraceuticals and food supplements has increased tremendously as alternative and/or complementary medicine to treat several pathologies, including inflammation. During the last decades, the biological properties of Citrus bergamia (bergamot) derivatives have obtained important scientific achievements, and it has been suggested their use in a context of a multitarget pharmacological strategy. Here, we present an overview of t…

0301 basic medicineCitrusnatural productsAnti-Inflammatory AgentsCitruantioxidant activityPharmaceutical SciencebergamotReviewPharmacologyAnalytical Chemistry0302 clinical medicinecomplementary and alternative medicinesDrug DiscoveryCitrus bergamiaeducation.field_of_studyTraditional medicineMedicine (all)3. Good healthAnti-Inflammatory AgentChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineComplementary medicineHumanmedicine.drug_classHerbal MedicinePopulationContext (language use)Natural productAnti-inflammatoryPlant ExtractAntioxidant activity; Bergamot; Citrus bergamia; Complementary and alternative medicines; Flavonoids; Inflammation; Natural products; Anti-Inflammatory Agents; Citrus; Herbal Medicine; Humans; Inflammation; Plant Extracts; Organic Chemistrylcsh:QD241-44103 medical and health sciencesNutraceuticallcsh:Organic chemistrySettore MED/43 - Medicina LegaleBiological propertymedicineHumansPhysical and Theoretical ChemistryeducationAntioxidant activity Bergamot Citrus bergamia Complementary and alternative medicines Flavonoids Inflammation Natural products Medicine (all);Plant Extractsbusiness.industryOrganic Chemistry030104 developmental biologyComplementary and alternative medicineinflammationflavonoidsCitrus bergamiaFlavonoidSettore BIO/14 - FarmacologiabusinessMolecules
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Safety of eterocoxib in subjects with histoty of adverse cutaneous reactions to ASA and/or non steroidal anti-inflammatory drugs

2008

ASAnon steroidal anti-inflammatory drugsSettore MED/09 - Medicina Internaeterocoxibadverse cutaneous reaction
researchProduct

Selective adsorption of oppositely charged PNIPAAM on halloysite surfaces: a route to thermo-responsive nanocarriers.

2018

Halloysite nanotubes were functionalized with stimuli-responsive macromolecules to generate smart nanohybrids. Poly(N-isopropylacrylamide)-co-methacrylic acid (PNIPAAM-co-MA) was selectively adsorbed into halloysite lumen by exploiting electrostatic interactions. Amine-terminated PNIPAAM polymer was also investigated that selectively interacts with the outer surface of the nanotubes. The adsorption site has a profound effect on the thermodynamic behavior and therefore temperature responsive features of the hybrid material. The drug release kinetics was investigated by using diclofenac as a non-steroidal anti-inflammatory drug model. The release kinetics depends on the nanoarchitecture of th…

AmideMaterials scienceTechnological applicationBioengineering02 engineering and technologyengineering.material010402 general chemistry01 natural sciencesHalloysiteLower critical solution temperatureAcrylic monomerchemistry.chemical_compoundAdsorptionthermo-responsive materialKaoliniteGeneral Materials ScienceElectrical and Electronic EngineeringNon-steroidal anti-inflammatory drugPoly (n isopropylacrylamide)Hybrid materialTargeted drug deliveryThermodynamic behaviors Controlled drug deliveryMechanical EngineeringHalloysiteGeneral Chemistry021001 nanoscience & nanotechnologyControlled release0104 chemical sciencesNanotubeHydrogelChemical engineeringchemistryMechanics of MaterialsSelective adsorptionSelf-healing hydrogelsengineeringPoly(N-isopropylacrylamide)0210 nano-technologyHybrid materialTemperature-responsivecontrolled releaseYarn Controlled releaseThermo-responsiveNanotechnology
researchProduct

Possible synergic action of non-steroidal anti-inflammatory drugs and glucosamine sulfate for the treatment of knee osteoarthritis: a scoping review

2022

Abstract Background Several studies have reported that glucosamine sulfate (GS) can improve knee osteoarthritis (OA) symptomatology. In parallel, the disease-modifying effects of non-steroidal anti-inflammatory drugs (NSAIDs) in knee OA have also been investigated. However, limited literature has reported the combined effect of GS and NSAIDs. The aim of this scoping review is to describe the scope and volume of the literature investigating the potential benefits and synergistic effect of a combination of GS and NSAIDs in patients with knee OA. Methods PubMed and Embase were searched for studies published from inception through April 2022, evaluating the effects of the combination of GS and …

GlucosamineObservational Studies as TopicRheumatologyCelecoxibAnti-Inflammatory Agents Non-SteroidalHumansPainOrthopedics and Sports MedicineCelecoxib Chondroprotective effect Cyclooxygenase 2 inhibitors Glucosamine sulfate Non-steroidal anti-inflammatory drugs OsteoarthritisSynergistic effectsOsteoarthritis KneeRandomized Controlled Trials as Topic
researchProduct

Hop-derived fraction rich in beta acids and prenylflavonoids regulates the inflammatory response in dendritic cells differently from quercetin: unvei…

2021

Dendritic cells (DCs) represent a heterogeneous family of immune cells that link innate and adaptive immunity and their activation is linked to metabolic changes that are essential to support their activity and function. Hence, targeting the metabolism of DCs represents an opportunity to modify the inflammatory and immune response. Among the natural matrices, Humulus lupulus (Hop) compounds have recently been shown to exhibit immunomodulatory and anti-inflammatory activity. This study aimed to evaluate the ability of specific Hop fractions to modulate DCs metabolism after stimulation with lipopolysaccharide (LPS) by an untargeted metabolomics approach and compare their effect with flavonol …

LipopolysaccharideHop fractions Dendritic cells metabolomics analysis Nrf2/Nqo1 pathwayAnti-Inflammatory AgentsSuccinic AcidInbred C57BLMass SpectrometryProinflammatory cytokineHop (networking)chemistry.chemical_compoundMiceMetabolomicsImmune systemBone MarrowAnimalsMetabolomicsAnimals; Anti-Inflammatory Agents; Bone Marrow; Citrulline; Dendritic Cells; Disease Models Animal; Flavonoids; Humulus; Inflammation; Mass Spectrometry; Metabolomics; Mice; Mice Inbred C57BL; Plant Extracts; Purines; Pyrimidines; Quercetin; Succinic AcidHumulusFlavonoidsInflammationChemistryAnimalPlant ExtractsGeneral MedicineDendritic CellsAcquired immune systemSettore CHIM/08 - Chimica FarmaceuticaCell biologyMice Inbred C57BLDisease Models AnimalPyrimidinesPurinesDisease ModelsCitrullineTumor necrosis factor alphaQuercetinQuercetinFood ScienceFoodfunction
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Physician–patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, pros…

2017

Background: Patients with multiple actinic keratoses (AKs) should be treated with field-directed therapy. Such treatments challenge patients’ adherence due to out-of-pocket costs, length of treatment and severity of local skin reactions (LSRs). Effective physician–patient communication (PPC) may buffer therapy-related distress, thus improving quality of life, treatment satisfaction and adherence. Objectives: We evaluated the interplay between PPC, LSR intensity (safety) and lesion clearance rates (effectiveness) on treatment satisfaction, quality of life and treatment adherence among patients with multiple AKs receiving topical field-directed therapies. Methods: In this observational, multi…

Male2708; infectious diseases; actinic keratosesDiclofenacActinictopical field‐directed therapyAnti-Inflammatory AgentsAntineoplastic AgentsAdministration CutaneousMedication AdherenceAdministration Cutaneous; Aged; Aged 80 and over; Anti-Inflammatory Agents Non-Steroidal; Antineoplastic Agents; Diclofenac; Diterpenes; Drug Eruptions; Female; Humans; Imiquimod; Italy; Keratosis Actinic; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Communication; Medication Adherence; Patient Satisfaction; Physician-Patient Relationsactinic keratoses2708; Infectious Diseases80 and overHumansLongitudinal StudiesPatient Reported Outcome MeasuresProspective Studiesactinic keratoseAgedAged 80 and overPhysician-Patient RelationsImiquimodtreatmentCommunicationAnti-Inflammatory Agents Non-SteroidalKeratosisMiddle AgedKeratosis ActinicInfectious DiseasesCutaneousItalyPatient SatisfactionAdministrationQuality of LifeFemaleDrug EruptionsDiterpenesSettore MED/35 - MALATTIE CUTANEE E VENEREENon-Steroidal2708
researchProduct

Clinical and Biological Heterogeneity in Children with Moderate Asthma

2003

To evaluate the relationship between inflammatory markers and severity of asthma in children, the amount of interleukin-8 (IL-8) and granulocyte/macrophage colony-stimulating factor (GM-CSF) released by peripheral blood mononuclear cells, exhaled nitric oxide (FE NO) levels, p65 nuclear factor-kappaB subunit, and phosphorylated IkBalpha expression by peripheral blood mononuclear cells were assessed in six control subjects, 12 steroid-naives subjects with intermittent asthma, and 17 children with moderate asthma. To investigate their predictive value, biomarker levels were correlated with the number of exacerbations during a 18-month follow-up period. We found that GM-CSF release was higher …

MaleExacerbationAnti-Inflammatory AgentsCritical Care and Intensive Care MedicineSynaptotagminsMedicineChildSalmeterol XinafoateCalcium-Binding ProteinMembrane GlycoproteinsRespiratory diseaseNF-kappa Binflammatory markersBronchodilator AgentsAnti-Inflammatory AgentSynaptotagmin IBiomarker (medicine)FemaleMembrane GlycoproteinAndrostadienes; Anti-Inflammatory Agents; NF-kappa B; Leukocytes Mononuclear; Membrane Glycoproteins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Synaptotagmins; Albuterol; Asthma; Child; Receptors Cell Surface; Nerve Tissue Proteins; Nitric Oxide; Synaptotagmin I; Calcium-Binding Proteins; Interleukin-8; Adolescent; Bronchodilator Agents; Male; Biological Markers; Femalemedicine.symptomHumanmedicine.drugPulmonary and Respiratory MedicineAdolescentNerve Tissue ProteinsReceptors Cell SurfaceInflammationNitric OxidePeripheral blood mononuclear cellFluticasone propionateHumansAlbuterolBronchodilator AgentAsthmaAndrostadienefluticasone propionatebusiness.industryCalcium-Binding ProteinsInterleukin-8Granulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseSynaptotagminAsthmaAndrostadienesasthma; inflammatory markers; fluticasone propionateNerve Tissue ProteinBiological MarkerExhaled nitric oxideImmunologyLeukocytes MononuclearFluticasonebusinessBiomarkersAmerican Journal of Respiratory and Critical Care Medicine
researchProduct